title: Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).
abstract: OBJECTIVE
  To determine mortality due to end-stage liver disease (ESLD) in a nationwide cohort of HIV-infected patients 5 years after the introduction of highly active antretroviral therapy (HAART) and to compare this with that observed before and during the early years of HAART.
  
  
  METHODS
  and methods: All departments of internal medicine and infectious diseases from the GERMIVIC Study Group prospectively recorded all deaths in HIV-infected patients during 2001. Sixty-five departments, following a total of 25 178 HIV-infected patients, participated in the study. Results were compared with those of previous surveys conducted using similar methodology in 1995 and 1997.
  
  
  RESULTS
  Among 265 deaths observed during 2001, 129 (48.7%) were related to AIDS, 38 (14.3%) to ESLD, and 98 (36.7%) to other causes. Mortality due to ESLD represented 28% of non AIDS-related deaths; 36 of the 38 patients (95%) dying from ESLD had chronic hepatitis C virus (HCV) infection. In 2001, deaths due to ESLD (14.3%) were significantly more frequent than in 1995 (1.5%; P < 0.01) and 1997 (6.6%; P < 0.01). During this interval, the prevalence of hepatocellular carcinoma as a cause of death increased (1995, 4.7%; 1997, 11%; 2001, 25%; P < 0.05), as did alcohol consumption (P < 0.01).
  
  
  CONCLUSIONS
  In the post-HAART era, ESLD due to HCV is a growing cause of mortality in HIV-infected patients. Increased longevity attributable to HAART, and a higher prevalence of alcohol consumption, are probably involved in this trend.
authors.affiliation: Service d'Hématologie Clinique, Hôpital Archet, Nice, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Rosenthal
authors.forename: Marilyne
authors.initials: M
authors.lastname: Poirée
authors.forename: Christian
authors.initials: C
authors.lastname: Pradier
authors.forename: Christian
authors.initials: C
authors.lastname: Perronne
authors.forename: Dominique
authors.initials: D
authors.lastname: Salmon-Ceron
authors.forename: Loic
authors.initials: L
authors.lastname: Geffray
authors.forename: Robert P
authors.initials: RP
authors.lastname: Myers
authors.forename: Philippe
authors.initials: P
authors.lastname: Morlat
authors.forename: Gilles
authors.initials: G
authors.lastname: Pialoux
authors.forename: Stanislas
authors.initials: S
authors.lastname: Pol
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
mesh_terms: D000328:Adult; D000368:Aged; D000428:Alcohol Drinking; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D016009:Chi-Square Distribution; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality* / Q000821:virology; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000401:mortality* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D011446:Prospective Studies; D018709:Statistics, Nonparametric
chemical_list: D019380:Anti-HIV Agents